Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes
December 04, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases both as standalone medicines and in combination with...
Roche expands hepatitis diagnostics portfolio to help clinicians diagnose and monitor patients with acute or chronic hepatitis B infection
November 27, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Elecsys® HBeAg quant is an immunoassay that can be used as an early marker of acute hepatitis B infection, as well as an indicator of chronic active hepatitis in combination with other laboratory...
Roche launches automated serology hepatitis E virus tests, including a test to detect acute HEV infections, recommended in the new WHO 2023 Essential Diagnostics List
November 16, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
It is estimated that one third of the global population could be at risk for infection with Hepatitis E virus.1The new tests allow clinicians to diagnose acute and chronic infections amongst patients...
Roche’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
November 14, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
If approved, Tecentriq subcutaneous (SC) would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approx. 80%1 The CHMP recommended Tecentriq SC for all...
Roche’s Elecsys NfL test, an important aid for those living with Multiple Sclerosis, is granted FDA Breakthrough Device Designation
November 09, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Roche Elecsys NfL aids in detection of disease activity in adults with Multiple Sclerosis supporting better disease management decisionsElecsys NfL offers a minimally invasive testing option that can...
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints
October 30, 2023 16:01 ET
|
F. Hoffmann-La Roche Ltd
Elevidys-treated boys aged 4-7 years with Duchenne showed an increase on the North Star Ambulatory Assessment (NSAA), a measure of motor function, compared to placebo at 52 weeks but the primary...
[Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO)
October 27, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
RVO is the third indication for Vabysmo, in addition to neovascular or ‘wet’ age-related macular degeneration and diabetic macular edemaApproval is based on two phase III studies demonstrating early...
[Ad hoc announcement pursuant to Art. 53 LR] Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant
October 23, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Roche will gain the rights to develop, manufacture and commercialise RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseasesRVT-3101 is a...
[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche mit gutem Verkaufswachstum trotz Rückgang der Nachfrage nach COVID-19-Produkten
October 19, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Basel, 19. Oktober 2023 Konzernverkäufe steigen in den ersten neun Monaten um 1%1 zu konstanten Wechselkursen (CER), mit einem deutlichen Wachstum von 7% im dritten Quartal Konzernverkäufe ohne...
[Annonce événementielle au sens de l’art. 53 RC] Roche fait état d’une bonne croissance de ses ventes malgré une baisse de la demande de produits liés au COVID-19
October 19, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Bâle, le 19 octobre 2023 Les ventes du groupe ont augmenté de 1 %1 à taux de change constants (TCC) au cours des neuf premiers mois, avec une forte augmentation de 7 % au troisième trimestreSans les...